

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Donna MENDRICK et al.)	
Application No.: 09/917,800)	Group Art Unit: 1631
Filed: July 31, 2001)	Examiner: Cheyne Dune Ly
For: Molecular toxicology modeling)	

Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, MAIL DD
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

RECEIVED

FEB 2 0 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Office Action or a Notice of Allowance. The Commissioner is hereby authorized to charge \$180.00 as specified by § 1.17(p) to Deposit Account No. 50-0310, for this Information Disclosure Statement under the provisions of 37 C.F.R. § 1.97(c).

Copies of the documents listed are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

Attorney Docket No. 44921-5038-US

Application No.: 09/917,800

Page 2

This submission does not represent that a search has been made or that no better art exists

and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If the Examiner applies a document as "prior art" against any claim in the

application and Applicants determine that the cited document does not constitute "prior art"

under United States law, Applicants reserve the right to present to the office the relevant facts

and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability

of the disclosed invention over the listed documents, should one or more of the documents be

applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby

authorized by this paper to charge any additional fees during the entire pendency of this

application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required,

including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR**

EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Dated: **February 18, 2004**

Morgan, Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel: 202-739-5870

Fax: 202-739-3001

Respectfully submitted

Morgan, Lewis & Bockius LLP

Registration No. 43,210

1-WA/2092445.1

INFORMATION DISCLOSURE CITATION			44921-5	Attorney Docket 44921-5038-US			Application No. 09/917,800	
(Use several sheets if necessary)				Applicant: Donna MENDRICK et al.				
	PTO Form 144	19	Filing D	ate: July 31,	2001	Group Art U	Jnit: 1631	
		U.S. PAT	ENT DOC	UMENTS				
ojtla P F Patent No.		Issue Date	Name	Name		Sub-class	Filing Date	
3	\					REC	EIVED	
EB 1 8 2004 &	/					· · · · · · · · · · · · · · · · · · ·		
P WATER ART						FEB 2	0 2004	
			-					
		FOREIGN P	ATENT D	OCUMEN'				
	Document	Date	Country	Class	Sub Class			
	No.					Yes	No	
	WO 03/085083	2003-10-16	PCT	C12N	 			
	WO 03/095624	2003-11-20	PCT	C12N				
	WO 03/100030	2003-12-04	PCT	C12N	 	_		
								
				 				
					+			
	<u> </u>							
		OTH	D DOCID	ADDRIEG.	<u> </u>			
,		ОТНЕ	R DOCUM	AENTS				
	Irizarry et al. (2 31(4):e15, 8 pp	2003), "Summaries c	of Affymetrix	GeneChip p	orobe level da	ata," Nucl Ac	ids Res	
	Nguyen et al. (2 data," Bioinform	2002), "Tumor class matics 18(1):39-50.	ification by	partial least s	quares using	microarray g	gene expression	
				· · · · · · · · · · · · · · · · · · ·				
								
	-						1-11-1-	
			Da	te Considered:				
xaminer:								